MD Anderson at the 2024 ASTRO Annual Meeting



Making Cancer History®

MDAnderson.org/ASTRO

Saturday, September 28	3	As of Sept. 24
11:30 a.m5:15 p.m.	ARRO 01 - ARRO Annual Resident Seminar	Room 145
1.55 2:25 n m	Keynote: Provider Wellness and Advice to Residents	
1:55-2:25 p.m.	Emma Holliday, M.D.	
12:30-5:00 p.m.	ARRO 02 - ASTRO-ARRO Medical Student Workshop	Room 143
	Clinical Oncology Research in Medical School	
1:00-1:30 p.m.	Kelsey Corrigan, M.D.	Moderator
	Gohar Manzar, M.D., Ph.D.	Panelist
2:40-3:00 p.m.	Thriving During Intern Year	
2.40-3.00 p.m.	Rehema Thomas, M.D.	Moderator
3:15-3:55 p.m.	Transitioning into Radiation Oncology Residency	
3.10-0.00 p.m.	Stephanie Dudzinski, M.D., Ph.D.	Panelist
3:45-5:00 p.m.	PRO 06 - Prevention and Management of Toxicity in Organs at Risk (OAR)	Room 146
3:47-4:07 p.m.	Lung OAR: Conventional Fractionated Treatment	Julianna Bronk, M.D., Ph.D.
4:07-4:27 p.m.	Lung OAR: Central and Ultracentral SBRT	Matthew Ning, M.D.
Sunday, September 29		
8:00-9:00 a.m.	SS 01 - Breast Cancer 1: Clinical Trials	Room 202
8:00-8:10 a.m.	Abstract 100 - Primary Outcome Analysis for Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized, Phase III Trial of Hypo- vs. Conventionally Fractionated Regional Nodal Irradiation (RNI)	Karen Hoffman, M.D.
8:00-9:00 a.m.	QP 01 - GU 4: GU Quick Pitch	Room 207
8:50-9:00 a.m.	Abstract 1005 - A Prospective Pilot Study Investigating 18F rhPSMA-7.3 P/MRI to Detect Recurrent Disease and Guide Radiotherapy Planning in Patients with Biochemically Recurrent Prostate Cancer Post-Pros	Devaki Shilpa Surasi, M.D.

PS 01 - Presidential Symposium: Innovations in Genitourinary Cancers: Session I - Renaissance of Radiotherapy for RCC	Ballroom A/B/C
Strategies and Evidence for SABR in RCC	Chad Tang, M.D.
ASPP 01 - 2024 Aspiring Scientists and Physicians Program for Underrepresented Populations	Room 143
Career Pathways Panel	Rehema Thomas, M.D.
Workshop 03 - No Longer "Taboo": An Interactive Workshop for Providers Navigating Compassionate Conversations with Sexual and Gender Minority (SGM) Patients	Room 145
Moderator	
Fostering a Safe Clinical Environment for Sexual and Gender Minority Adolescents and Young Adults	Benjamin Schrank, M.D., Ph.D.
Questions and Answers	
EDU 05 - Advances in Cancer Immunotherapy (ACI) Radiation Oncology Program	Room 209
The State of Clinical Translation	James Welsh, M.D.
SS 04 - PRO/QoL/Survivorship 1: New frontiers in patient reported outcomes and survivorship	Room 204
Abstract 116 - Patient-Reported Functional Decline Following Active Surveillance (AS), Radical Prostatectomy (RP), External Beam Radiation without Androgen Deprivation Therapy (EBRT w/o ADT), or Low-Dose-Rate Brachy	Patrick Carriere, M.D., Ph.D.
Workshop 04 - Grant Writing Workshop	Room 150
Welcome	Debra Yeboa, M.D.
Specific Aims	Kristy Brock, Ph.D.
Questions and Answers	Debra Yeboa, M.D.
PQA 01 - PQA 01 Lung Cancer/Thoracic Malignancies and Diversity, Equity and Inclusion in Healthcare Poster Q&A	Hall C
n of Private Schooling with Matching at Highly Ranked Radiation Programs: An Analysis of the Texas Star Dataset	Elaine Cha, M.D.
ed Hypofractionated Radiotherapy for the Definitive Management of all Cell Lung Cancer: A Systematic Review	Badr Id Said, M.D.
SS 10 - DHI 1	Room 207B
Abstract 157 - I-SABR-SELECT: A Radiomics-Based Model for Personalized Immunotherapy for Early-Stage Non-Small Cell Lung Cancer	Maliazurina Saad, Ph.D.
Personalized Immunotherapy for Early-Stage Non-Small Cell Lung	Maliazurina Saad, Ph.D.
	Strategies and Evidence for SABR in RCC ASPP 01 - 2024 Aspiring Scientists and Physicians Program for Inderrepresented Populations Career Pathways Panel Vorkshop 03 - No Longer "Taboo": An Interactive Workshop for Providers Navigating Compassionate Conversations with Sexual and Gender Minority (SGM) Patients Moderator Fostering a Safe Clinical Environment for Sexual and Gender Minority Adolescents and Young Adults Questions and Answers EDU 05 - Advances in Cancer Immunotherapy (ACI) Radiation Directory Program The State of Clinical Translation SS 04 - PRO/QoL/Survivorship 1: New frontiers in patient reported outcomes and survivorship Abstract 116 - Patient-Reported Functional Decline Following Active Burveillance (AS), Radical Prostatectomy (RP), External Beam Radiation without Androgen Deprivation Therapy (EBRT W/o ADT), or low-Dose-Rate Brachy Vorkshop 04 - Grant Writing Workshop Velcome Specific Aims Questions and Answers PQA 01 - PQA 01 Lung Cancer/Thoracic Malignancies and Diversity, Equity and Inclusion in Healthcare Poster Q&A of Private Schooling with Matching at Highly Ranked Radiation Programs: An Analysis of the Texas Star Dataset and Hypofractionated Radiotherapy for the Definitive Management of all Cell Lung Cancer: A Systematic Review

Abstract 2314 - Deep Learning-Based Auto Contouring of Mandibular Sub-Volumes Based on the ClinRad System for Spatial Localization of Osteoradionecrosis of the Jaw		Laia Humbert-Vidan, Ph.D.
Abstract 2368 - Feasibility of Longitudinal Relaxation Rate Mapping with Non-Cartesian Sequences on a 1.5T MR-Linac		Lucas McCullum
Abstract 2406 - From Adults to Pediatrics: The Reliability and Reproducibility of Al Auto-Contouring in Pediatric Cancer Treatment		Sogand Sadeghi, Ph.D.
	y of Cardiac Chamber Auto-Segmentation and Dose Optimization for MR-Radiotherapy of Central Lung Cancer	Jinzhong Yang, Ph.D.
4:45-6:00 p.m.	EDU 09 - Update on ASTRO's Partial Breast Irradiation Guidelines: Case-Based Interactive Discussion	Room 202
4:47-4:59 p.m.	Panel Discussion of Clinical Case Scenarios Addressing Implementation of Recommendations: KQ 1-4	Simona Shaitelman, M.D.
	Monday, September 30	
8:00-9:00 a.m.	PQA 03 - PQA 03 Gynecological Cancer, Pediatric Cancer, and Professional Development Poster Q&A	Hall C
	and Dosimetric Characteristics Associated with Mandible diatric Patients Treated with Proton Therapy for Head and Neck	Sage Copling
Abstract 3541 - Adaptive Gynecologic Malignancie	Magnic Resonance Guided Radiation Therapy for Definitive Treatment of s	Kathryn Marqueen, M.D.
10:45 a.m12:00 p.m.	SS 15 - GU 3: Prostate Cancer Treatment Intensification	Room 202
10:45-10:55 a.m.	Abstract 181 - Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus	Karen Hoffman, M.D.
11:25-11:35 a.m.	Abstract 185 - Hypofractionated, Dose-Escalated Radiation vs. Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial	Comron Hassanzadeh, M.D.
10:45a.m12:00 p.m.	PQA 04 - PQA 04 Palliative Care and Central Nervous System	
	Poster Q&A	Hall C
Abstract 2525 - Memory t	Poster Q&A ract sparing using Diffuse tensor imaging in radiation planning of low-	Ory Haisraely, M.D.
grade glioma		
grade glioma Abstract 2526 - Re-irradia	ract sparing using Diffuse tensor imaging in radiation planning of low- ation of anaplastic meningioma. Local control factors and toxicity report of Brain-Directed Therapy for Patients with Melanoma Brain Mastases	Ory Haisraely, M.D.
grade glioma Abstract 2526 - Re-irradia Abstract 2545 - Utilization Treated with Ipilimumab a Abstract 2570 - Reduced	ract sparing using Diffuse tensor imaging in radiation planning of low- ation of anaplastic meningioma. Local control factors and toxicity report of Brain-Directed Therapy for Patients with Melanoma Brain Mastases	Ory Haisraely, M.D. Ory Haisraely, M.D.
grade glioma Abstract 2526 - Re-irradia Abstract 2545 - Utilization Treated with Ipilimumab a Abstract 2570 - Reduced Radionecrosis and Lymp Abstract 2573 - Feasibility	ract sparing using Diffuse tensor imaging in radiation planning of low- ation of anaplastic meningioma. Local control factors and toxicity report of Brain-Directed Therapy for Patients with Melanoma Brain Mastases and Nivolumab Treatment Volumes for Glioblastoma Result in Lower Rates of	Ory Haisraely, M.D. Ory Haisraely, M.D. Troy Kleber, M.D. Susan McGovern, M.D.,
grade glioma Abstract 2526 - Re-irradia Abstract 2545 - Utilization Treated with Ipilimumab a Abstract 2570 - Reduced Radionecrosis and Lymp Abstract 2573 - Feasibilit Diffusion Tensor Imaging Radiosurgery	ract sparing using Diffuse tensor imaging in radiation planning of low- ation of anaplastic meningioma. Local control factors and toxicity report of Brain-Directed Therapy for Patients with Melanoma Brain Mastases and Nivolumab Treatment Volumes for Glioblastoma Result in Lower Rates of nopenia: A Pooled Analysis of and Outcomes of Navigated Transcranial Magnic Stimulation Based	Ory Haisraely, M.D. Ory Haisraely, M.D. Troy Kleber, M.D. Susan McGovern, M.D., Ph.D.
grade glioma Abstract 2526 - Re-irradia Abstract 2545 - Utilization Treated with Ipilimumab a Abstract 2570 - Reduced Radionecrosis and Lymp Abstract 2573 - Feasibilit Diffusion Tensor Imaging Radiosurgery	ract sparing using Diffuse tensor imaging in radiation planning of low- ation of anaplastic meningioma. Local control factors and toxicity report of Brain-Directed Therapy for Patients with Melanoma Brain Mastases and Nivolumab Treatment Volumes for Glioblastoma Result in Lower Rates of nopenia: A Pooled Analysis of and Outcomes of Navigated Transcranial Magnic Stimulation Based Tractography of Motor Pathways in Patients Undergoing Stereotactic	Ory Haisraely, M.D. Ory Haisraely, M.D. Troy Kleber, M.D. Susan McGovern, M.D., Ph.D. Jordan McDonald, M.D.
grade glioma Abstract 2526 - Re-irradia Abstract 2545 - Utilization Treated with Ipilimumab a Abstract 2570 - Reduced Radionecrosis and Lymp Abstract 2573 - Feasibilit Diffusion Tensor Imaging Radiosurgery Abstract 2601 - Off-Proto	ract sparing using Diffuse tensor imaging in radiation planning of low- ation of anaplastic meningioma. Local control factors and toxicity report of Brain-Directed Therapy for Patients with Melanoma Brain Mastases and Nivolumab Treatment Volumes for Glioblastoma Result in Lower Rates of nopenia: A Pooled Analysis of and Outcomes of Navigated Transcranial Magnic Stimulation Based Tractography of Motor Pathways in Patients Undergoing Stereotactic col Radiotherapy in Phase III Metastatic Solid Tumor Trials	Ory Haisraely, M.D. Ory Haisraely, M.D. Troy Kleber, M.D. Susan McGovern, M.D., Ph.D. Jordan McDonald, M.D. Alexander Sherry, M.D.

11:32-11:47 a.m.	A Pathway to Bring Electron FLASH to Clinical Standard of Care	Devarati Mitra, M.D., Ph.D.
10:45 a.m12:00 p.m.	SS 19 - Bio 3: Genomics and Biomarkers	Room 150
11:25-11:35 a.m.	Abstract 212 - Characterizing Radiation Induced Subclonal Kinics in Pancreatic Ductal Adenocarcinoma	Vincent Bernard Pagan, M.D., Ph.D.
3:00-4:00 p.m.	QP 03 - HSR 2: Health Services Research/Global Health Quick Pitch	Room 143
	Moderator	Fumiko Chino, M.D.
3:00-4:00 p.m.	PQA 05: Breast Cancer and Nonmalignant Disease Poster Q&A	Hall C
Abstract 2699 - Re-Irrad Ipsilateral Breast Cancer	iation Toxicity and Survival Outcomes for Locoregionally Recurrent or New	Kamaria Lee, M.D.
3:00-4:00 p.m.	EDU 26 - Out from the Shadows and into the Spotlight: Making Brachytherapy Available and Sustainable for Our Patients and Providers	Room 152
3:17-3:32 p.m.	The Plot Thickens: Building in Value for Brachytherapy	Melissa Joyner, M.D.
5:00-6:00 p.m.	PQA 06 - PQA 06 Biology and Patient Reported Outcomes Poster Q&A	Hall C
Abstract 2763 - Disparition	es in Completion of Patient-Reported Outcomes in Thoracic Radiation	Monzer Alatrach
Abstract 2827 - The Rad	iotherapy Information Gap in Survivorship Care Plans	Ramez Kouzy, M.D.
5:00-6:00 p.m.	SS 25 - Lung 1: Randomized Trials for Lung Cancer	Room 207
5:10-5:20 p.m.	Abstract 243 - Long-Term Outcomes of a Prospective Randomized Trial of Passive Scattering Proton Therapy vs. Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer	Tingshi Su, Ph.D.
5:00-6:00 p.m.	SS 27 - Heme 1: Glowing results: Clinical Trials of Radiation in Lymphoma	Room 144
	Moderator	Jillian Gunther, M.D., Ph.D.
5:00-6:00 p.m.	International 06 - Building Radiation Capacity in Africa through Collaborations in Research and Training - Voices from ASTRO and AORTIC Members	Room 204
5:14-5:26 p.m.	Cervical Cancer - Education and Training for LMIC	Anuja Jhingran, M.D.
5:00-6:00 p.m.	EDU 33 - Challenging Cases in Palliative Care	Room 209
5:20-5:30 p.m.	Considerations of Palliative Radiation for a Radioresistant Histology	Subha Perni, M.D.
5:00-6:00 p.m.	SS 26 - Sarcoma 1: Optimizing Treatment Outcomes in Soft Tissue Sarcoma and Melanoma	Room 143
5:50-6:00 p.m.	Discussant	Ashleigh Guadagnolo, M.D.

	Tuesday, October 1	
8:00-9:00 a.m.	SS 28 - Lung 2: Novel Lung Cancer Investigations	Room 147
8:10-8:20 a.m.	Abstract 258 - Exploratory Analysis of Plasma Protein Abundance Kinics from I-SABR, A Randomized Phase II Trial of Stereotactic Ablative Radiotherapy with or without Nivolumab in Stage I-IIA or Recurrent Non-Small	Aaron Seo, M.D., Ph.D.
8:00-9:00 a.m.	QP 07 - Palliative 2: The Next Generation in Palliation: From MR-guided SABR to Patient Selection and Everything in Between	Room 140
8:20-8:30 a.m.	Abstract 1038 - Final Report of a Phase I/II Study of BMS-986156 (Glucocorticoid-Induced TNFR-Related Gene [GITR] Agonist) with Ipilimumab or Nivolumab with/without Stereotactic Ablative Radiotherapy in Patients with	Xinyan Xu, M.D.
8:00-9:00 a.m.	EDU 38 - Hypofractionation for Soft-Tissue Sarcoma	Room 144
8:30-8:47 a.m.	Hypofractionated, 3-Week, Preoperative Radiotherapy for Patients with Soft Tissue Sarcomas (HYPORT-STS)	Andrew Bishop, M.D.
8:00-9:00 a.m.	QP 08 - Prof Dev 1: Professional Development and Medical Education - Quick Pitch	Room 158
8:50-9:00 a.m.	Abstract 1047 - Optimizing Leadership Development Strategies for Enhanced Leader and Team Impact	Amanda Woods, Ph.D.
40.45.4.45	QP 10 - PRO/QoL/Survivorship 2: Quick Pitch	Room 140
12:45-1:45 p.m.	Moderator	Ann Klopp, M.D., Ph.D.
12:45-2:00 p.m.	PQA 07 - PQA 07 Gastrointestinal Cancer and Sarcoma/Cutaneous Tumors Poster Q&A	Hall C
	f Sexual Dysfunction and Prevalence of Estrogen Supplementation after men with Early-Onset Rectal Cancer	Angelica Arzola
Abstract 3069 - Sinonas	al Melanoma Outcomes after Neoadjuvant Immunotherapy	Aya Salem, M.D.
Abstract 3079 - MRI as Chemoradiation Therap	a Biomarker for Pelvic Floor Atrophy in Rectal Cancer Patients Undergoing	Rehema Thomas, M.D.
12:45-2:00 p.m.	SS 29 - Bio 4: Immunotherapy and Immune Response	Room 150
1:15-1:25 p.m.	Abstract 266 - A Microbial-Inspired Antibody-Drug Conjugate Unleashes Macrophage Functionalities for Cancer Immunotherapy	Benjamin Schrank, M.D., Ph.D.
	Macrophage Functional and Canoci minutes rapy	
2:30-3:00 p.m.	GW 04 - Grant Writing Office Hours IV	East Salon C, Early Career & Mentoring Lounge
2:30-3:00 p.m.		East Salon C, Early Career
2:30-3:00 p.m. 2:30-3:30 p.m.	GW 04 - Grant Writing Office Hours IV	East Salon C, Early Career

Abstract 1068 - Hypofractionated Radiation Therapy for Unresectable or Bulky Mastatic Melanoma

Devarati Mitra, M.D., Ph.D.

3:00-3:10 p.m.

2:30-3:45 p.m.	SS 34 - GYN 2: Strategies and Innovations of Clinical Trials in Gynecologic Cancers	Room 209
2:50-3:00 p.m.	Abstract 298 - IMMUNOCERV Phase II Trial Combining the HPV- Specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer	Adam Grippin, M.D., Ph.D.
2:30-3:45 p.m.	SS 35 - GI 2: Colorectal Cancer: Innovation through Preservation and Observation	Room 150
3:20-3:30 p.m.	Discussant	Emma Holliday, M.D.
2:30-3:45 p.m.	PQA 08 - PQA 08 Genitourinary Cancer, Patient Safety, and Nursing/Supportive Care Poster Q&A	Hall C
	Abstract 3144 - Severe Genitourinary Events Following Definitive Radiation Therapy for Patients with Locally Advanced and Metastatic Bladder Cancer: A Single Institution Experience	
Abstract 3146 - Stereotac Imaging or Computed To	tic Body Radiotherapy for Prostate Cancer with Magnetic Resonance mography Guidance	Enoch Chang, M.D.
4:00-5:00 p.m.	PQA 09 - PQA 09 Hematologic Malignancies and Digital Health Innovations Poster Q&A	Hall C
Abstract 3365 - Bridging I Mantle Cell Lymphoma	Radiotherapy prior to Brexucabtagene Autoleucel for Relapsed/Refractory	Ahmed Fetooh, M.D.
Abstract 3385 - Uncertainty Quantification in Machine Learning Radiotherapy Applications - A Scoping Review		Zaphanlene Kaffey
Abstract 3416 - Multiomic of Multiple Toxicity Outco	Based Bayesian Network Toxicity Modeling for Simultaneous Prediction mes in NSCLC	Saurabh Nair
3434 - Independent Validation and Performance Comparison of Published Radiation Pneumonitis NTCP Models for IMRT, Immunotherapy and Proton Therapy Cohorts		Ramon Salazar
4:00-5:00 p.m.	EDU 51 - Advancing Combined Modality Trials in Radiotherapy: Integrating Preclinical and Clinical Insights	Room 150
4:17-4:32 p.m.	Enhancing the Successful Translation of Research into Clinical Practice in Radiation Oncology	Steven Lin, M.D., Ph.D.
4:00-5:00 p.m.	EDU 52 - Artificial Intelligence in Precision Oncology: Early Clinical Applications for Your Radiation Oncology Clinic	Room 144
4:38-4:50 p.m.	Overcoming Barriers: Strategies for Adopting AI in Resource-Limited Stings - Addressing the Challenges and Solutions for Integrating AI in Clinics with Limited Resources	Laurence Court, Ph.D.
4:00-5:00 p.m.	EDU 55 - Challenging Cases in the Management of Squamous Cell Carcinoma of the Skin	Room 143
4:26-4:38 p.m.	Challenging Cases in Management of Cutaneous Squamous Cell Carcinoma	Karen Choi, M.D.
4:00-5:00 p.m.	SS 37 - H&N 1: Envisioning the Future: Leading Edge Research in HPV-Associated Oropharyngeal Cancer	Room 145
4:40-4:50 p.m.	Abstract 316 - The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamous	Li Wang, M.D., Ph.D.

5:15-6:15 p.m.	SS 39 - HSR 1: Moving Beyond the Beam: Health Services Research in Policy, Practice, and Payment?	Room 144
5:45-5:55 p.m.	Abstract 326 - Medical Misinformation about Cancer Recurrence Risks in Patients with Breast Cancer Who Received Radiation	Fumiko Chino, M.D.
5:55-6:05 p.m.	Abstract 327 - Prevalence of Control Arm Overperformance as a Contributing Factor to Optimism Bias in Phase 3 Oncology Clinical Trials	Ansel Nalin, M.D., Ph.D.
5:15-6:15 p.m.	EDU 59 - How High Can We Go - How Low Should We Aim? Normal Tissue Dose/Volume Constraints in Lymphoma Radiation Therapy Planning	Room 143
5:47-6:02 p.m.	Constraints in Different Scenarios in the Daily Lymphoma Practice, including Reirradiation in the Relapse Sting	Chelsea Pinnix, M.D., Ph.D.
5:15-6:15 p.m.	QP 18 - Bio 5: Genomics and Biomarkers II	Room 152
6:05-6:15 p.m.	Abstract 1106 - Impact of Cancer Therapy on Clonal Hematopoiesis Mutations and Subsequent Clinical Outcomes	Kevin Nead, M.D.
	Wednesday, October 2	
8:00-9:00 a.m.	QP 19 - Breast Cancer 4: Quick Pitch	Room 204
8:00-8:10 a.m.	Abstract 1107 - Circulating Tumor Cell Clearance Kinics in Patients Undergoing Adjuvant Radiotherapy for Node-Positive Breast Cancer: A Prospective Observational Cohort Study	Chelain Goodman, M.D., Ph.D.
10:30-11:30 a.m.	QP 24 – Bio 6: Immunotherapy and Immune Response II	Room 143
10:50-11 a.m.	Abstract 1139 - Cross-Cancer Analysis Reveals Distinct Pattern of Immune Modulation during Curative Radiotherapy	Badr Id Said, M.D.
10:30-11:45 a.m.	PQA 10 - PQA 10 Head & Neck Cancer and Health Services Research/Global Oncology Poster Q&A	Hall C
	Like an Electric Shock:" Patient Perspectives on the Expectations, of-Life Impact of Androgen Deprivation Therapy (ADT) for Prostate	Maheen Ansari
	er Phase III Trial of Chemoradiation (CRT) with IMPT vs. IMRT for s Cell Carcinoma (OPSCC): Secondary Analysis of Association of nent Modality, Emer	Adam Grippin, M.D., Ph.D.
Abstract 3690 - Association of Biologically Effective Dose and Survival in Patients Receiving Head and Neck Stereotactic Body Radiation Therapy		César Márquez, M.D., Ph.D.
Abstract 3703 - Characterization of Radiation Response of Muscular Tissue in the Head and Neck Using Dynamic Contrast Enhanced Magnic Resonance Imaging		Samuel Mulder
Abstract 3728 - Assessing Pandemic and Overall Su	g the Relationship of Radiation Treatment Breaks with the COVID-19 rvival	Aaron Seo, M.D., Ph.D.
12:30-1:30 p.m.	QP 25 - Phys 13: Clinical Data and Dose Evaluation	Room 144
12:40-12:50 p.m.	Abstract 1144 - Development of Prediction Model for Right and Left Liver Hypertrophy to Estimate Response in Patients Treatments Simulated with Photon Based 3DCRT and IMRT Plans	Aashish Gupta
12:30-1:30 p.m.	QP 26 - Bio 7: Radiation Cancer Biology and Immune Response	Room 151
1:20-1:30 p.m.	Abstract 1154 - A Lymph Node Immune Score (LNIS) Identifies Prognostic Immune Phenotypes Shared across Head and Neck Cancers	Michael Spiotto, M.D., Ph.D.